Article Contents ::
- 1 The Brand Name DIARLOP Has Generic Salt :: Nalidixic
- 2 DIARLOP Is From Company Jagsonpal Priced :: Rs. 16.16
- 3 DIARLOP have Nalidixic is comes under Sub class Quinolones of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Quinolones
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DIARLOP Has Generic Salt :: Nalidixic
DIARLOP Is From Company Jagsonpal Priced :: Rs. 16.16
DIARLOP have Nalidixic is comes under Sub class Quinolones of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Quinolones
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Nalidixic | SUS | Rs. 16.16 | 30ML |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 30ML |
| DIARLOP | Jagsonpal | 300MG/5ML | 30ML | Rs. 16.16 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Jagsonpal :: DIARLOP | Nalidixic | Anti Infectives | Quinolones |
Indications for Drugs ::
Lower urinary tract infections, Shigellosis
Drug Dose ::
ral Uncomplicated lower urinary tract infections Adult: 1 g 4 times daily for 1-2 wk. Long-term therapy: Reduce daily dose to 2 g. Child: >3 mth: 50 mg/kg daily in 4 equally divided doses. Long-term therapy: Reduce dose to 30 mg/kg daily. Prophylaxis: 15 mg/kg bid. Shigellosis Adult: 1 g 4 times daily for 5 days. Child: >3 mth: 15 mg/kg 4 times daily for 5 days. Hepatic impairment: Reduced doses should be considered.
Contraindication ::
Hypersensitivity. History of convulsive disorders or porphyria. Infants <3 mth. Severe renal impairment. Drug Precautions ::
Hepatic or moderate renal impairment, severe cerebral arteriosclerosis, G6PD deficiency. Monitor blood counts, renal and hepatic function for treatment >2 wk. Children <18 yr. Elderly. Avoid exposure to sunlight or sunlamps. Pregnancy and lactation. Drug Side Effects ::
Nausea, vomiting, diarrhoea, abdominal pain; photosensitivity reactions, allergic rash, urticaria, pruritus; visual disturbances, headache, dizziness or vertigo, drowsiness, confusion, depression, excitement, hallucinations, toxic psychoses or convulsions (especially after large doses), intracranial hypertension (especially in infants and young children), metabolic acidosis; peripheral neuropathies, muscular weakness, myalgia; arthralgia, tendon damage; cholestatic jaundice, thrombocytopenia, leucopenia. Potentially Fatal: Erythema multiforme and Stevens-Johnson syndrome; anaphylactoid reactions. Auto-immune haemolytic anaemia (particularly in elderly patients).
Pregnancy category ::
3
Drug Mode of Action ::
Nalidixic acid is a 4-quinolone antibacterial. It interferes with the replication of bacterial DNA by inhibiting DNA gyrase activity. It acts against gram-negative bacteria including E. coli, Proteus, Klebsiella, Enterobacter, Salmonella and Shigella spp.
Drug Interactions ::
Absorption reduced by sucralfate, and divalent and trivalent cations e.g. aluminium, calcium, iron, magnesium, zinc. Excretion reduced and plasma concentrations increased with probenecid. Reduced effects with chloramphenicol, nitrofurantoin, tetracycline. Potentially Fatal: Fatal haemorrhagic enterocolitis may occur when used with high-dose melphalan in children. Increased risk of nephrotoxicity with ciclosporin. May increase effects of oral anticoagulants e.g. warfarin.
